A total of 960 participants (96%) had type 2 diabetes, with 468 of 997 (47%) requiring insulin, 153 (15%) taking sodium-glucose cotransporter 2 inhibitors, and 102 (10%) taking L agonists at baseline. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.